Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TPX-0046 |
Synonyms | |
Therapy Description |
TPX-0046 inhibits RET and SRC, potentially resulting in decreased tumor cell growth (Annals of Oncology (2019) 30 (suppl_5): v159-v193) |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TPX-0046 | TPX0046|TPX 0046 | RET Inhibitor 53 SRC Inhibitor 31 | TPX-0046 inhibits RET and SRC, potentially resulting in decreased tumor cell growth (Annals of Oncology (2019) 30 (suppl_5): v159-v193) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RET G810R | Advanced Solid Tumor | predicted - sensitive | TPX-0046 | Preclinical - Cell culture | Actionable | In a preclinical study, TPX-0046 treatment led to inhibition of cell proliferation in a transformed cell line expressing RET G810R in culture (J Clin Oncol 38, no. 15_suppl (May 20, 2020) 3616-3616). | detail... |
RET G810C | Advanced Solid Tumor | predicted - sensitive | TPX-0046 | Preclinical - Cell culture | Actionable | In a preclinical study, TPX-0046 treatment led to inhibition of cell proliferation in a transformed cell line expressing RET G810C in culture (J Clin Oncol 38, no. 15_suppl (May 20, 2020) 3616-3616). | detail... |
RET G810S | Advanced Solid Tumor | predicted - sensitive | TPX-0046 | Preclinical - Cell culture | Actionable | In a preclinical study, TPX-0046 treatment led to inhibition of cell proliferation in a transformed cell line expressing RET G810S in culture (J Clin Oncol 38, no. 15_suppl (May 20, 2020) 3616-3616). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04161391 | Phase Ib/II | TPX-0046 | Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations | Terminated | USA | 1 |